IL154754A0 - Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals - Google Patents
Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticalsInfo
- Publication number
- IL154754A0 IL154754A0 IL15475401A IL15475401A IL154754A0 IL 154754 A0 IL154754 A0 IL 154754A0 IL 15475401 A IL15475401 A IL 15475401A IL 15475401 A IL15475401 A IL 15475401A IL 154754 A0 IL154754 A0 IL 154754A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceuticals
- arginine
- medicament
- prevention
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 2
- 239000004475 Arginine Substances 0.000 title 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001984A IT1318689B1 (it) | 2000-09-12 | 2000-09-12 | Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla |
| PCT/EP2001/010398 WO2002022134A1 (en) | 2000-09-12 | 2001-09-07 | Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154754A0 true IL154754A0 (en) | 2003-10-31 |
Family
ID=11445780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15475401A IL154754A0 (en) | 2000-09-12 | 2001-09-07 | Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040014693A1 (es) |
| EP (1) | EP1318817A1 (es) |
| JP (1) | JP2004508406A (es) |
| KR (1) | KR20030045066A (es) |
| CN (1) | CN1466458A (es) |
| AR (1) | AR030635A1 (es) |
| AU (1) | AU2002214974A1 (es) |
| BR (1) | BR0113844A (es) |
| CA (1) | CA2421920A1 (es) |
| CZ (1) | CZ2003957A3 (es) |
| EA (1) | EA200300368A1 (es) |
| EE (1) | EE200300096A (es) |
| HU (1) | HUP0301026A2 (es) |
| IL (1) | IL154754A0 (es) |
| IT (1) | IT1318689B1 (es) |
| MX (1) | MXPA03002114A (es) |
| NO (1) | NO20031115L (es) |
| NZ (1) | NZ524677A (es) |
| PE (1) | PE20020432A1 (es) |
| PL (1) | PL361844A1 (es) |
| SK (1) | SK4562003A3 (es) |
| WO (1) | WO2002022134A1 (es) |
| ZA (1) | ZA200302866B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080249001A1 (en) * | 2006-10-25 | 2008-10-09 | Ajinomoto Co. Inc. | Agents that alleviate side-effects caused by chemotherapy agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5780446A (en) * | 1996-07-09 | 1998-07-14 | Baylor College Of Medicine | Formulations of vesicant drugs and methods of use thereof |
| GB9921960D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and amino acids |
| US6436913B1 (en) * | 2000-07-25 | 2002-08-20 | Pharmacia & Upjohn Company | Use of estramustine phosphate in the treatment of bone metastasis |
-
2000
- 2000-09-12 IT IT2000MI001984A patent/IT1318689B1/it active
-
2001
- 2001-09-07 AU AU2002214974A patent/AU2002214974A1/en not_active Abandoned
- 2001-09-07 WO PCT/EP2001/010398 patent/WO2002022134A1/en active IP Right Grant
- 2001-09-07 EE EEP200300096A patent/EE200300096A/xx unknown
- 2001-09-07 US US10/363,998 patent/US20040014693A1/en not_active Abandoned
- 2001-09-07 HU HU0301026A patent/HUP0301026A2/hu unknown
- 2001-09-07 CA CA002421920A patent/CA2421920A1/en not_active Abandoned
- 2001-09-07 KR KR10-2003-7003557A patent/KR20030045066A/ko not_active Application Discontinuation
- 2001-09-07 NZ NZ524677A patent/NZ524677A/en unknown
- 2001-09-07 MX MXPA03002114A patent/MXPA03002114A/es not_active Application Discontinuation
- 2001-09-07 CZ CZ2003957A patent/CZ2003957A3/cs unknown
- 2001-09-07 PL PL01361844A patent/PL361844A1/xx not_active Application Discontinuation
- 2001-09-07 CN CNA018165168A patent/CN1466458A/zh active Pending
- 2001-09-07 EP EP01983475A patent/EP1318817A1/en not_active Withdrawn
- 2001-09-07 IL IL15475401A patent/IL154754A0/xx unknown
- 2001-09-07 EA EA200300368A patent/EA200300368A1/ru unknown
- 2001-09-07 BR BR0113844-8A patent/BR0113844A/pt not_active IP Right Cessation
- 2001-09-07 SK SK456-2003A patent/SK4562003A3/sk unknown
- 2001-09-07 JP JP2002526384A patent/JP2004508406A/ja not_active Withdrawn
- 2001-09-10 AR ARP010104268A patent/AR030635A1/es unknown
- 2001-09-11 PE PE2001000911A patent/PE20020432A1/es not_active Application Discontinuation
-
2003
- 2003-03-11 NO NO20031115A patent/NO20031115L/no unknown
- 2003-04-11 ZA ZA200302866A patent/ZA200302866B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2421920A1 (en) | 2002-03-21 |
| SK4562003A3 (en) | 2003-09-11 |
| AR030635A1 (es) | 2003-08-27 |
| HUP0301026A2 (hu) | 2003-10-28 |
| IT1318689B1 (it) | 2003-08-27 |
| CZ2003957A3 (cs) | 2003-09-17 |
| NZ524677A (en) | 2005-02-25 |
| ITMI20001984A0 (it) | 2000-09-12 |
| JP2004508406A (ja) | 2004-03-18 |
| US20040014693A1 (en) | 2004-01-22 |
| AU2002214974A1 (en) | 2002-03-26 |
| EE200300096A (et) | 2005-02-15 |
| ZA200302866B (en) | 2004-04-28 |
| PL361844A1 (en) | 2004-10-04 |
| CN1466458A (zh) | 2004-01-07 |
| ITMI20001984A1 (it) | 2002-03-12 |
| WO2002022134A8 (en) | 2004-03-04 |
| WO2002022134A1 (en) | 2002-03-21 |
| EA200300368A1 (ru) | 2003-08-28 |
| EP1318817A1 (en) | 2003-06-18 |
| PE20020432A1 (es) | 2002-05-11 |
| BR0113844A (pt) | 2003-06-03 |
| NO20031115D0 (no) | 2003-03-11 |
| MXPA03002114A (es) | 2003-06-19 |
| KR20030045066A (ko) | 2003-06-09 |
| NO20031115L (no) | 2003-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144730A (en) | Use of statin drug in the preparation of a medicament and as a medicament for the treatment of diabetic neuropathy | |
| HK1076387A1 (en) | Use in the preparation of a combination medicament for the treatment or prevention of an immunoinflammatory disorder | |
| HK1050839A1 (en) | Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state | |
| HUP0101293A3 (en) | Aspb28-human insulin comprising pharmaceutical composition administered by inhalation and their use | |
| EP1231864A4 (en) | Tissue-Attachable Drug Applicator and Method of Use Thereof | |
| IL199437A (en) | Using at least one strain of bacteria to make a dietetic and / or pharmacist's medicine for the prevention or treatment of hypoxular disease | |
| AU6311301A (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
| EP1600168A3 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder | |
| AU7445901A (en) | Pharmaceutical compositions comprising cannabidiol derivatives | |
| IL136512A0 (en) | Intravenous infusion administration set | |
| AU2002246152A1 (en) | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | |
| IL130784A0 (en) | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same | |
| AU2002213698A1 (en) | Needleless syringe for the subcutaneous delivery of therapeutic agents | |
| ZA200203156B (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders. | |
| GB2368525B (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| IL146032A0 (en) | Use of n-acetylcysteine for the preparation of a medicament suitable for intravenous administration to prevent oxidative stress in dialysed patients | |
| HUP0203903A3 (en) | Solubilized pharmaceutical composition for parenteral administration and its use | |
| FI951683A (fi) | Yhdisteiden, joilla on antiglukokortikoidiaktiivisuus, käytt¦ sellaisten lääkkeiden valmistamiseksi, jotka on tarkoitettu huumausaineiden tai huumausaineseosten spontaaniin tai laukaistuun vieroitusoireyhtymäänliittyvien oireiden estämiseen tai hoitoon, ja niitä sisältäviä | |
| CA2396209A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| IL154754A0 (en) | Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals | |
| EP1583545A4 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE | |
| AU2003229656A1 (en) | A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms | |
| GB0007788D0 (en) | Method to evaluate the therapeutic and toxic effects related to drug administration | |
| Kharrasov et al. | Evaluation of the efficacy of anesthesiologic protection in induced abortion | |
| SI1384477T1 (sl) | Uporaba derivatov pirazolina pri pripravi zdravila za preprecevanje in/ali zdravljenje proliferatnih celicnih bolezni |